Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Employees - 15,
CEO - Mr. Ian Chan,
Sector - Healthcare,
Country - US,
Market Cap - 148.15M
Altman ZScore(max is 10): -7.78, Piotroski Score(max is 10): 3, Working Capital: $-7480594, Total Assets: $7858053, Retained Earnings: $-17811367, EBIT: -16083540, Total Liabilities: $19541036, Revenue: $122000
AryaFin Target Price - $-0.08 - Current Price $2.07 - Analyst Target Price $-
| Ticker | ABP |
| Index | - |
| Curent Price | 2.07 |
| Change | 38.93% |
| Market Cap | 148.15M |
| Average Volume | 733.34K |
| Income | -1.73M |
| Sales | 0.00M |
| Book Value/Share | -1.45 |
| Cash/Share | 0.02 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 4 |
| Moving Avg 20days | 3.31% |
| Moving Avg 50days | -68.04% |
| Moving Avg 200days | -78.74% |
| Shares Outstanding | 51.52M |
| Earnings Date | - |
| Inst. Ownership | 0.50% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 102.88 |
| Price/FCF | - |
| Quick Ratio | 0.17 |
| Current Ratio | 0.17 |
| Debt/Equity | - |
| Return on Assets | -7.62% |
| Return on Equity | -35.20% |
| Return on Investment | - |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 34.06 |
| BETA(β) | -0.36 |
| From 52week Low | 117.89% |
| From 52week High | -84.08% |
| EPS | -0.21 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -251.79% |
| Sales Y/Y | - |
| EPS Q/Q | -902.44% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.76 |
| Perf Week | 35.29% |
| Perf Month | -39.30% |
| Perf Quarter | -81.10% |
| Perf Year | -80.04% |
| Perf YTD | -80.43% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer